Mr. Sheehy On video. “HIV/AIDS: Progress and Promise in Stem Cell Research.” CIRM HIV/AIDS.
CIRM grantees show progress toward a cure for HIV/AIDS Boston. By Jeff Sheehy. At the 18th Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, two members of CIRM’s HIV/AIDS Disease Team led by John Zaia at City of Hope presented new research showing the team’s progress toward the clinic.The team’s overall goal is to use technology developed by Sangamo Biosciences to modify the blood-forming stem cells of people infected with HIV. The modifications would effectively remove the doorway protein-called CCR5-the HIV virus uses to enter immune cells. The less than one percent of the population who lack CCR5 are naturally resistant to HIV infection and one HIV patient in Berlin who received a complete bone marrow transplant from someone born lacking the CCR5 receptor has been functionally “cured” of HIV.In a presentation on Monday, Sangamo Biosciences released preliminary data from 6 HIV patients in its gene therapy clinical trial targeting T-cells, which are the primary immune cells invaded by the HIV virus. The study uses Sangamo’s zinc finger gene modification technique to remove the CCR5 receptor from T-cells taken from the patients with HIV. Those modified T cells were then returned to the patients’ blood system. The patients saw both survival and expansion of the modified T-cells-a critical finding since this implies some competitive advantage for cells protected by CCR5 deletion over cells that are not protected. END EXCERPTS.
CIRM claims they do not partner with any organization. Yet, CIRM has partnered with the AIDS Health Foundation. “CIRM has signed a co-funding agreement with the AIDS Health Care Foundation.”….Jeff Sheehy, CIRM Board. On that video is the caption: Jeff Sheehy, CIRM Board, HIV/AIDS Advocate.